Cargando…
Retracted: Efficacy, Safety, and Tumor Marker Inhibition of Apatinib Combined with Conventional Chemotherapy Regimens for Patients with Advanced Triple-Negative Breast Cancer
Autor principal: | and Alternative Medicine, Evidence-Based Complementary |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307265/ https://www.ncbi.nlm.nih.gov/pubmed/37388035 http://dx.doi.org/10.1155/2023/9879023 |
Ejemplares similares
-
Retracted: Camrelizumab and Apatinib Combined with Radiotherapy Is Effective in Advanced Oligometastatic Non-Small-Cell Lung Cancer
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023) -
Retracted: Low-Dose Apatinib Improves the Prognosis of Patients with Recurrent High-Grade Gliomas
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023) -
Retracted: Analysis of the Efficacy of Multidrug Combination Chemotherapy Regimens for Osteosarcoma and the Management of Chemotherapeutic Reactions
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023) -
Retracted: Chemotherapy with a TP Regimen in Combination with Stereotactic Radiotherapy Could Significantly Optimize the Clinical Efficacy of NSCLC Treatment
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023) -
Retracted: Expression of PD-L1 and BRCA1 in Triple-Negative Breast Cancer Patients and Relationship with Clinicopathological Characteristics
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)